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Abstract 
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoper-
able disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab and 
nivolumab has recently shown increased survival compared to standard chemotherapy, but most patients do not 
respond and improvements are called for. Telomerase is expressed in mesothelioma cells, but only sparsely in normal 
tissues and is therefore an attractive target for therapeutic vaccination. Vaccination against telomerase is tolerable 
and has shown to induce immune responses associated with increased survival in other cancer types. There is a 
well-founded scientific rationale for the combination of a telomerase vaccine and checkpoint inhibition to improve 
treatment response in MPM patients.
Methods: NIPU is a randomized, multi-centre, open-label, phase II study comparing the efficacy and safety of 
nivolumab and ipilimumab with or without telomerase vaccine in patients with inoperable malignant pleural meso-
thelioma after first-line platinum-based chemotherapy. Participants (n = 118) are randomized 1:1 into two treatment 
arms. All participants receive treatment with nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 
6 weeks) until disease progression, unacceptable toxicity or for a maximum of 2 years. Patients randomised to the 
experimental arm receive 8 intradermal injections of UV1 vaccine during the first three months of treatment. Tumour 
tissue, blood, urine, faeces and imaging will be collected for biomarker analyses and exploration of mechanisms for 
response and resistance to therapy.
Discussion: Checkpoint inhibition is used for treatment of mesothelioma, but many patients still do not respond. 
Increasing therapy response to immunotherapy is an important goal. Possible approaches include combination 
with chemotherapy, radiotherapy, targeted therapy and other immunotherapeutic agents. Predictive biomarkers 
are necessary to ensure optimal treatment for each patient and to prevent unnecessary side effects. This trial seeks 
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Background
Malignant pleural mesothelioma (MPM) is a rare and 
aggressive tumour originating from the cells lining the 
mesothelial surface in the lungs. Median overall survival 
(OS) is ~ 1 year [1]. Asbestos exposure is linked to devel-
opment of the disease [2]. Most patients diagnosed with 
malignant pleural mesothelioma are inoperable and have 
been treated with cisplatin in combination with pem-
etrexed which has been the standard of care first-line 
therapy worldwide since 2003.
Intra-tumour infiltration of CD8+ T cells is associ-
ated with improved outcome in MPM [3] and a high 
expression of PD-L1 is associated with poor prognosis 
in this group of patients [4]. Monotherapy using pem-
brolizumab, nivolumab or avelumab has demonstrated 
a response rate of 9.3–20% [5–7]. The only phase 3 trial 
combining PD-1 and CTLA4 inhibition (Checkmate 
743) showed an increased median survival from 14.1 to 
18.1 months, and a duration of response of 11.0 vs 6.7 
months in the combination arm vs the chemotherapy 
arm, respectively [8]. However, almost all the benefit was 
seen in patients with biphasic or sarcomatoid disease, 
whereas those with epithelioid disease did not benefit 
significantly. Grade 3 or 4 toxicity with the combination 
has been found in 17–34% of patients and has generally 
been manageable. The most common toxicities have been 
from the skin, gastrointestinal tract, hormone system and 
infusion reactions [8]. Based on these results, the FDA 
approved the combination of ipilimumab and nivolumab 
in the first line setting in October 2020.
Although these results are encouraging, the response 
rates seen are moderate compared to what has been doc-
umented for the combination of checkpoint inhibitors in 
other cancer diseases, indicating that checkpoint inhibi-
tors alone are not enough to trigger an activation of an 
immune response against MPM. MPM is often found to 
be immunologically ‘cold’ tumours (lacking immune cell 
infiltration), but previous studies have indicated that 
treatment can increase immune cell infiltration in such 
cold MPM tumours by oncolytic virus [9]. Combining 
checkpoint inhibition with a treatment that can increase 
lymphocyte infiltration in the tumour could increase the 
response rates. One such approach is to use a vaccine 
aiming to activate an immune response directed against 
tumour-related antigens, and to combine the vaccine 
with checkpoint inhibitors.
UV1 is a therapeutic cancer vaccine directed against 
telomerase produced by Ultimovacs ASA. Telomerase 
maintains telomere length in dividing cells and is con-
sidered essential for tumour growth. It is expressed at 
high levels in more than 85% of human tumours, but 
only sparsely in normal tissues [10]. Since telomerase is 
an essential enzyme and universally expressed by most 
tumour cells, it represents a unique cancer antigen as a 
basis for immunotherapy.
In the NIPU-trial, UV1 will be tested in combination 
with ipilimumab and nivolumab to assess its ability to 
increase the treatment response in patients with MPM in 
the second line setting. This study was designed prior to 
the positive results of the CheckMate 743 trial, and may 
also inform the potential for UV1 vaccination in the first 
line setting.
Methods/design
Oslo University Hospital is sponsor of the study. We have 
established collaborations for patient recruitment with 
cancer centres in Australia, Denmark, Sweden and Spain. 
University of Western Australia is sponsor for the study 
in Australia. Patient recruitment started in June 2020 
and is expected to finish by May 2022. Initiation of the 
trial was postponed due to the COVID-19 pandemic. By 




To evaluate and compare the efficacy of nivolumab and 
ipilimumab with or without UV1-vaccine in patients 
with inoperable malignant pleural mesothelioma pro-
gressing after first-line platinum-based chemotherapy. 
The primary end point will be progression free survival 
(PFS) evaluated by modified response evaluation criteria 
in solid tumours (mRECIST) [11, 12] as determined by 
blinded, independent central review (BICR).
to improve treatment response by combining checkpoint inhibition with a telomerase vaccine and also to explore 
mechanisms for treatment response and resistance. Knowledge gained in the NIPU study may be transferred to the 
first line setting and to other cancers with limited benefit from immunotherapy.
Trial registration: ClinicalTrials.gov: NCT04300244, registered March 8th, 2020, https:// clini caltr ials. gov/ ct2/ show/ NCT04 
300244? term= NIPU& draw= 2& rank=1.
Keywords: Malignant pleural mesothelioma, Telomerase vaccine, Immunotherapy, hTERT, Nivolumab, Ipilimumab, 
Biomarker, Immune response
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Secondary objectives
• To compare overall survival (OS), objective response 
rate (ORR), disease control rate (DCR), time to 
response (TTR) and duration of response (DOR) 
according to Response Evaluation Criteria in Solid 
Tumours, version 1.1 (Modified RECIST), in patients 
who receive nivolumab and ipilimumab with patients 
who receive nivolumab and ipilimumab in combina-
tion with UV1.
• To evaluate changes from baseline in patient-
reported outcomes (PROs) of lung cancer symp-
toms, patient functioning, and health-related quality 
of life (HRQoL) in patients who receive nivolumab 
and ipilimumab compared to patients who receive 
nivolumab and ipilimumab in combination with 
UV1.
• To determine tolerability in patients who receive 
nivolumab and ipilimumab compared to patients 
who receive nivolumab and ipilimumab in combina-
tion with UV1.
Exploratory/translational objectives
• To characterise the TCR repertoire in patients receiv-
ing checkpoint inhibition alone compared with in 
combination with UV1 vaccination.
• To evaluate tumour mutational burden (TMB) as a 
predictive biomarker of response to therapy.
• To assess any difference in immune cell infiltration 
in tumour pre- and post-treatment with checkpoint 
inhibition alone or with UV1 vaccination.
• To assess vaccine-specific T-cell response in the 
blood cells of patients treated with UV1 vaccination.
• To assess any correlation between the microbial com-
position in faeces and treatment response.
• Evaluate dual-time PET as a predictive marker of 
therapy response and assess the ability of dual-time 
PET to distinguish between different cell types in the 
tumour.
Study design
This is a randomized, multi-centre, open-label, proof 
of concept study comparing the efficacy and safety of 
nivolumab and ipilimumab with or without UV1 in 
patients with inoperable malignant pleural mesothelioma 
after first-line platinum-based chemotherapy.
The patients (n = 118) will be randomized 1:1 into two 
treatment arms (see Fig. 1):
A Nivolumab and ipilimumab plus 8 UV1 vaccinations.
B Nivolumab and ipilimumab alone.
Treatment will be continued until disease progres-
sion, unacceptable toxicity or for a maximum of 2 years. 
Because of the potential for pseudo progression/tumour 
immune infiltration, this study will allow patients to 
remain on study treatment after apparent radiographic 
progression, provided the risk/benefit ratio is judged to 
be favourable.
Biological material will be sampled, and transla-
tional explorative analyses will be performed to iden-
tify biomarkers and reveal mechanisms of response and 
resistance
Dosage
• Nivolumab: 240 mg every 2 weeks for 2 years until 
progression or unacceptable toxicity.
• Ipilimumab: 1 mg/kg every 6 weeks for 2 years until 





Ipilimumab 1mg/kg every 6 weeks and 
nivolumab 240 mg every 2 weeks
plus 8 UV1 vaccinaons
Ipilimumab 1mg/kg every 6 weeks and 
nivolumab 240 mg every 2 weeks





Fig. 1 Study design of the NIPU trial. Patients with MPM and progression after first line platinum-based chemotherapy are randomised (1:1) to 
ipilimumab and nivolumab alone or in combination with UV1 vaccine.
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• UV1 vaccination (arm A only): 8 intradermal injec-
tions with 300 μg UV1 and 75 μg GM-CSF (sargra-
mostim) during the first 13 weeks. The first 3 UV1 
vaccinations will begiven in week 1, one in week 2, 
followed by four UV1 vaccinations throughout the 
following 11 weeks, totalling eight vaccinations. The 
first three vaccinations of UV1 will be given prior to 
the first infusion of nivolumab and ipilimumab.
Overview of the study procedures and treatment can 
be found in Table 1.
Rationale for the choice of vaccine
Telomerase activation is a major factor contributing to 
cancer proliferation, immortality, and invasiveness [13–
15], and its activation is documented in MPM [16, 17]. 
Tumour telomerase expression is correlated with poor 
outcome for many cancers [18–20], conversely, spon-
taneously occurring telomerase-directed CD4+ T-cell 
responses have recently been identified as a positive 
prognostic factor in NSLCL [21], substantiating its rel-
evance as a target for vaccination in thoracic malignan-
cies. Vaccination with UV1 induces immune responses 
directed at telomerase reverse transcriptase (hTERT), 
the catalytic subunit of the telomerase complex. By tar-
geting this essential cancer protein, there are limited 
possibilities for resistance mutations to develop, as loss 
of hTERT would restrict tumour proliferation and metas-
tasis. Furthermore, by mounting a CD4+ Th1 response 
(i.e. secretion of IFN-γ, TNFα and IL-2), the vaccine 
aims to induce an inflammatory tumour microenviron-
ment to further stimulate the expansion of secondary 
effector cells. UV1 is administered with granulocyte-
macrophage colony-stimulating factor (GM-CSF) as an 
adjuvant. The safety and immunological response of the 
vaccine given as monotherapy have been investigated in 
two clinical phase I/II trials [22, 23]. The combination of 
the UV1 vaccine with ipilimumab in metastatic malig-
nant melanoma patients has been investigated in a phase 
I/IIa trial (n  =  12) (Aamdal E. et  al. Manus in prep.) 
(NCT02275416). Together, these studies have shown 
that UV1 is generally safe and well tolerated. Common 
adverse events related to UV1 include pruritus, ery-
thema, fatigue, diarrhoea, pain and rash. Overall, six of 
the 52 patients vaccinated with UV1 (12%) experienced 
serious adverse events that were related to UV1 and/or 
GM-CSF, of these five were of allergic origin. All events 
resolved without sequelae.
Across the three phase I/II-studies conducted with 
UV1, vaccine-specific immune responses were observed 
in 78% (range 67–91%) of patients across the differ-
ent cancer types (and HLA allele types), supporting the 
Table 1 Overview of study treatment and procedures
Weeks Study period
Up to 2 years EOT Q3M safety FU Q3M 
survival 
FU–4–0 1 2 3–5 6–7 12 Q6W
Enrolment
 Informed consent ×
 Randomisation ×
Treatment arm A
 UV1 × × × × × × × ×
 Nivolumab Q2W × × × × × × × × ×
 Ipilimumb Q6W × × × ×
Treatment arm B
 Nivolumab Q2W × × × × × × × × × ×
 Ipilimumb Q6W × × × ×
Procedures
 CT × × × × × ×
 Dual-time PET × × ×
 Biopsy × × ×
 Study blood samples × × × ×
 HR-QoL × × × × ×
 Clinical e×amination Q2W × × × × × × × × × × ×
 AE/SAE Q2W × × × × × × × × × × ×
 Disease status/survival × ×
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universality of the vaccine. Survival time for patients who 
responded immunologically was longer than for patients 
who did not respond immunologically to the vaccine, and 
survival time correlated with the breadth of the vaccine-
specific immune response.
In summary, UV1 is safe alone and in combination with 
checkpoint inhibitors and trials in other cancers show 
that UV1 induces vaccine-specific immune response 
associated with survival.
Rationale for the choice of immunotherapy
The rationale for combining UV1 vaccination with 
immune checkpoint inhibitors is for the vaccine to prime 
a meaningful T cell response that can be enhanced by 
the checkpoint inhibitors to facilitate the activity of the 
tumour-specific T cells in the tumour microenviron-
ment. Several pre-clinical studies have shown improved 
anti-tumour responses upon combination of vaccine and 
checkpoint inhibitors [24]. Data from clinical studies 
combining anti-immune checkpoint blockade and vac-
cines are still limited, but some early trials show encour-
aging results and were recently reviewed [25]. PD-1 and 
CTLA-4 checkpoints differentially affect CD8+ and 
CD4+ T-cell phenotypes [26] and recent data indicate 
that immune responses induced by anti-CTLA-4 and 
anti-PD-1 checkpoint-blockade are driven by different 
cellular mechanisms [27]. This indicates that vaccination 
with long peptides containing both CD4 and CD8 T-cell 
epitopes combined with both ipilimumab and nivolumab 
could be expected to have a maximal synergistic effect.
UV1-specific immune responses were induced in 11 
out of 12 melanoma-patients treated with UV1 vaccine 
in combination with ipilimumab. The immune response 
appeared more frequently and rapidly than in patients 
treated with UV1 alone [22], [23] (Aamdal et  al. manu-
script submitted), suggesting a synergistic effect of block-
ing of CTLA-4 and vaccination with UV1. Of 12 patients, 
one patient developed a complete response, three 
patients obtained a partial response, and two achieved 
stable disease as best overall response. The safety, clinical 
and immunological responses of the UV1 vaccine when 
used in combination with the PD-1 immune checkpoint 
inhibitor pembrolizumab is currently under investigation 
in a phase I/II clinical trial in patients (N = 30) with met-
astatic malignant melanoma (NCT03538314).
In summary, ipilimumab and nivolumab has shown 
clinical benefit in patients with MPM and trials in other 
tumour groups have found immunological synergy 
between ipilimumab and UV1.
Patient selection




Administration of study treatment will be performed in 
a setting with emergency medical facilities and staff who 
are trained to monitor for and respond to medical emer-
gencies. All adverse events and serious adverse events 
will be recorded during the trial and for up to 30 days 
after the last dose of study drug or until the initiation of 
another anti-cancer therapy, whichever occurs first. After 
this period, investigators should report serious adverse 
events and adverse events of special interest that are 
believed to be related to prior treatment with study drug. 
Events will be graded according to NCI CTCAE v5.0.
Table 2 Selected inclusion and exclusion criteria
Selected inclusion criteria Selected exclusion criteria
1. Histologically and/or cytologically confirmed MPM 1. Disease suitable for curative surgery
2. Unresectable disease, not candidate for curative surgery 2. Previous treatment with a PD1 or PD-L1 inhibitor
3. Measurable disease, defined as at least one lesion (CT or MRI) that is suitable 
for repeated assessment
3. Non-pleural mesothelioma e.g. mesothelioma arising in other organs
4. Available unstained archived tumour tissue sample 4. Active second malignancy other than non-melanoma skin cancer or 
cervical carcinoma in situ
5. Previously treated with at least one line of platinum doublet 5. Symptomatic or uncontrolled brain metastases requiring concurrent 
treatment
6. ECOG performance status of 0–1 6. Known history of leptomeningeal carcinomatosis
7. Willing to provide archived tumour tissue and blood samples for research 7. Active or prior documented autoimmune or inflammatory disorders
8. Adequate organ function 8. History of primary immunodeficiency
9. Age ≥ 18 years 9. History of allogeneic organ transplant
10. Uncontrolled intercurrent illness
11. Active infection
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Dose reduction considerations (selected points)
• Dose reduction of nivolumab or ipilimumab is not 
permitted, apart from changing the dosing intervals 
for ipilimumab to every 12th week.
• For any concomitant conditions already apparent at 
baseline, the dose modifications will apply accord-
ing to the corresponding shift in toxicity grade, if the 
investigator feels it is appropriate. For example, if a 
patient has grade 1 asthenia at baseline that increases 
to grade 2 during treatment, this will be considered a 
shift of one grade and treated as grade 1 toxicity for 
dose-modification purposes.
• When several toxicities with different grades of 
severity occur at the same time, the dose modifi-
cations should be according to the highest grade 
observed.
• If, in the opinion of the investigator, a toxicity is con-
sidered to be due to some component of the treat-
ment leading to a dose delay, the other component(s) 
may be administered if there is no contraindication.
• If a patient experiences a grade 3 or 4 adverse event 
considered probably related to ipilimumab, the ipili-
mumab dosing interval should be extended to every 
12 weeks. The ipilimumab dose should be kept at 
1mg/kg.
• Patients may temporarily suspend study treatment 
with nivolumab/ipilimumab if they experience an 
adverse event that requires a dose to be held.
• If nivolumab is held because of adverse events for 
> 42 days (6 weeks), the patient will be discontin-
ued from nivolumab treatment.
• If ipilimumab is held because of adverse events for 
> 126 days (18 weeks), the patient will be discon-
tinued from nivolumab treatment.
• If the patient is likely to benefit from resuming 
nivolumab/ipilimumab after a longer hold than 
allowed (6 or 18 weeks), the study drug may be 
restarted with the approval of the Sponsor. If a 
patient must be tapered off steroids used to treat 
adverse events, nivolumab may be held for > 42 
days until steroids are discontinued or reduced to 
prednisone dose equivalent ≤ 10 mg/day.
• The treating physician may use discretion in modi-
fying or accelerating the dose modification guide-
lines described depending on the severity of toxicity 
and an assessment of the risk versus benefit for the 
patient, with the goal of maximizing patient compli-
ance and access to supportive care.
• Dose modification of GM-CSF (sargramostim) or 
UV1 is not allowed in this study. If ipilimumab and 
nivolumab are withheld during the study treatment 
period, UV1 vaccination must also be withheld. UV1 
vaccinations will only be reintroduced if both ipili-
mumab and nivolumab are reintroduced.
• UV1 vaccination and/or ipilimumab and nivolumab 
not administered will not be replaced during the 
study treatment period.
Independent data monitoring
An independent data monitoring committee (IDMC) has 
pre-planned assessment of the safety of the trial 4 and 13 
weeks after the first 6 and 14 patients have started treat-
ment. All the IDMC assessments has been successfully 
completed.
Sample collection/biobanking
An extensive research program will be conducted. The 
patient informed consent form will allow for performing 
biomarker analyses, immunological studies, gene profil-
ing and studies of tumour evolution/heterogeneity dur-
ing treatment, as well as comparison with data/material 
from other studies.
(1) Tumour biopsies collected pre, during and post 
therapy (time of progression). If sufficient tissue 
is available, three biopsies will be obtained at each 
timepoint, and prioritized in the following order:
(a) FFPE tissue.
(b) Snap-frozen tumour biopsies.
(c) Fresh tumour cells/tumour infiltrating lympho-
cytes frozen as cell suspension (selected sites).
(2) A separate biopsy (snap-frozen) will be taken at 
week 6 from those patients who consent to the pro-
cedures.
(3) Blood samples collected pre-, during and post-ther-
apy:
(a) Peripheral blood mononuclear cells, processed 
with gradient centrifugation and frozen on liq-
uid nitrogen (selected sites).
(b) Plasma/serum, separated and frozen.
(c) Circulating tumour cells (only if sufficient 
resources available).
(4) Urine samples collected pre-, during and post-ther-
apy.
(5) Faecal samples collected at baseline, tumour evalu-
ation timepoints and progression.
(6) Dual-time PET analyses at baseline, 6 weeks, 1 year 
and at progression (selected sites).
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Statistical analyses
Under the null hypothesis, the PFS hazard ratio (HR), 
for ipilimumab and nivolumab in combination with UV1 
(ipi/nivo/UV1) vs ipilimumab and nivolumab (ipi/nivo) is 
assumed to be 1.00. Under the alternative hypothesis, the 
HR is assumed to be 0.60. To test the null hypothesis with 
80% power and a 1-sided alpha level of 0.10, a total of 69 
PFS events are required. Based on the INITIATE trial 
[28], with 12 months median follow-up it is expected that 
69% of patients treated with ipi/nivo will have progressed 
and, with a HR of 0.60, it is further expected that 51% of 
patients treated with ipi/nivo/UV1 will have progressed. 
With an expected accrual rate of 5 patients per month, 
a total N=118 patients randomized into the trial over a 
24-month period and followed for a minimum of 2–3 
months after the last patient is randomized will yield the 
69 PFS events required.
Discussion
The NIPU study is designed as a randomized phase 2 
trial. Randomization will provide useful data on both tox-
icity and efficacy. Since the combination of UV1 with ipil-
imumab and nivolumab has not previously been studied 
in patients with MPM, a phase 2 study giving indications 
of both toxicity and efficacy is warranted before starting 
a phase 3 trial for both ethical and economic reasons. 
The trial is open-labelled as placebo vaccination with 
observation time was impractical and time-consuming 
for both patients and nurses and blinding was not con-
sidered necessary for a phase 2 trial with a blinded inde-
pendent centrally reviewed primary endpoint.
As treatment guidelines change, the patient population 
eligible for clinical trials change. One challenge with the 
NIPU trial is that patients treated with checkpoint inhi-
bition in first line are not eligible for the trial and once 
the ipilimumab/nivolumab treatment regime is imple-
mented, the patient population eligible for the study will 
rapidly reduce. Until that time, however, the patients 
have few treatment options in the second line and the 
clinical data gained from this trail may be relevant for the 
first line setting in the future. Inclusion has started and 
shows that patients are eager to participate in the trial.
The translational analyses constitute an important part 
of the trial. As immunotherapy is being established as 
part of the treatment available to patients with MPM, it 
is important to gain knowledge about biological mecha-
nisms contributing to treatment response or resistance.
Tumour biopsies will be collected at baseline and at 
6 weeks after start of treatment to evaluate the tumour 
microenvironment and its association with therapy 
effect. Characterization of immune cell subsets will be 
done in the tumour and in the circulation, including 
T-cells, B cells, NK cells, myeloid-derived suppressor 
cells, or subpopulations Immune cells in the tumour 
will be characterized. Specific immune response against 
the UV1 vaccine will be analysed as will the changes in 
clonality of the T cell receptor repertoire in response to 
therapy.
Previous studies have shown that the temporal 
dynamics of uptake of 18F-Fluorodeoxyglucose (FDG) 
varies between benign and malignant lesions [29, 30]. 
The uptake kinetics of FDG (reflected by glucose con-
sumption rates) may vary between different cell types, 
and we hypothesize that we can differentiate between 
cancer and immune cells by so-called dual-time PET 
[29]. We test this by comparing the cellular composi-
tion (tumour cells and various immune cells) at base-
line and at 6 weeks after treatment with dual-time PET 
(scans obtained 60 and 120 min after injection of FDG).
The composition of the gut microbiome has been 
found associated with response to immunotherapy and 
the use of antibiotics has been associated with reduced 
effect of check point inhibition as a result of unfavour-
able alterations to the gut microbiome [31, 32]. We col-
lect faeces at baseline, 6 weeks, at regular intervals and 
at progression for DNA extraction and deep sequenc-
ing. Microbiota profiles will be linked to immune 
responses in circulation and in the tumour to identify 
microbes associated with immune response to treat-
ment. Information about concomitant medication will 
be available.
Exploration of biological mechanisms of action and 
biomarker analyses will be performed on tumour tissue, 
but we will also search for reliable biomarkers using 
less invasive methods such as blood, imaging, urine 
and faeces. Based on results from the CheckMate 743 
trial indicating more pronounced benefit for sarcoma-
toid/non-epithelioid tumours [8], the clinical effect and 
the biological basis for the effect in the epithelioid and 
non-epithelioid tumours will be explored. The knowl-
edge gained from these translational studies will be of 
value in understanding the mechanisms for therapy 
effect and resistance also in the first line setting.
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